High expression of PRMT5 significantly correlated with poor overall survival p < 0.05, relapse-free survival with p < 0.05, and progression-free survival with p < 0.05, except disease-specific survival with p > 0.05 in HCC patients (Figure 2a–d). Here, PRMT5 is linked to hepatocellular carcinoma.